Diabetes and fragility fractures - A burgeoning epidemic?

Bone

Volumn 43, Issue 1, 2008, Pages 3-6

  Epstein, Sol ^a   LeRoith, Derek ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Fragility fractures; IGF 1; Insulin; Neuropathy thiazolidinediones; Obesity; Osteoporosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLIN; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; ROSIGLITAZONE;

BONE DENSITY; BONE DEVELOPMENT; DIABETES MELLITUS; DISEASE ASSOCIATION; EDITORIAL; EPIDEMIC; FRACTURE; FRAGILITY FRACTURE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITION; OBESITY; OSTEOPOROSIS; PATHOPHYSIOLOGY; SIDE EFFECT;

AGED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; OBESITY; PPAR GAMMA;

EID: 44949208283     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.03.017     Document Type: Editorial

References (42)

1. Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 359 (2002) 1929-1936
2. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
3. Goodman W.G., and Hori M.T. Diminished bone formation in experimental diabetes. Relationship to osteoid maturation and mineralization. Diabetes 33 (1984) 825-831
4. Hampson G., Evans C., Petitt R.J., Evans W.D., Woodhead S.J., Peters J.R., et al. Bone mineral density, collagen type 1 alpha 1 genotypes and bone turnover in premenopausal women with diabetes mellitus. Diabetologia 41 (1998) 1314-1320
5. Inzerillo A.M., and Epstein S. Osteoporosis and diabetes mellitus. Rev Endocr Metab Disord 53 (2004) 261-268
6. Gunczler P., Lanes R., Paz-Martinez V., Martins R., Esaa S., Colmenares V., et al. Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally. J Pediatr Endocrinol Metab 11 (1998) 413-419
7. Kemink S.A., Hermus A.R., Swinkels L.M., Lutterman J.A., and Smals A.G. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 5 (2000) 295-303
8. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int 18 (2007) 427-444
9. Nicodemus K.K., and Folsom A.R. Iowa Women's Health Study. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 7 (2001) 1192-1197
10. Hofbauer L.C., Brueck C.C., Singh S.K., and Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 22 (2007) 1317-1328
11. Rakel A., Sheehy O., Rahme E., and Lelorier J. Does diabetes increase the risk for fractures after solid organ transplantation? A nested case-control study. J Bone Miner Res 22 12 (2007) 1878-1884
12. Lipscombe L.L., Jamal S.A., Booth G.L., and Hawker G.A. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 30 (2007) 835-884
13. Janghorbani M., Feskanich D., Willett W.C., and Hu F. Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study. Diabetes Care 29 (2006) 1573-1578
14. Schwartz A.V., Sellmeyer D.E., Strotmeyer E.S., Tylavsky F.A., Feingold K.R., Resnick H.E., et al. Health ABC Study. Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res 4 (2005) 596-603
15. Tirabassi R.S., Flanagan J.F., Wu T., Kislauskis E.H., Birckbichler P.J., and Guberski D.L. The BBZDR/Wor rat model for investigating the complications of type 2. Diabetes 54 (2005) 2727-2733
16. Amir G., Rosenmann E., Sherman Y., Greenfeld Z., Ne'eman Z., and Cohen A.M. Osteoporosis in the Cohen diabetic rat: correlation between histomorphometric changes in bone and microangiopathy. Lab Invest 82 (2002) 1399-1405
17. Fernández A.M., Kim J.K., Yakar S., Dupont J., Hernandez-Sanchez C., Castle A.L., et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 15 (2001) 1926-1934
18. Fritton J.C., Berman D., Inagaki K., LeRoith D., Schaffler M.B., and Jepsen K.J. Slender long bone in a skeletal-muscle specific IGF-1/Insulin receptor defective mouse (Feb. 11-14, 2007), The Orthopaedic Research Society, San Diego, CA Abstract number: 1331
19. Phornphutkul C., Wu K.Y., and Gruppuso P.A. The role of insulin in chondrogenesis. Mol Cell Endocrinol 249 (2006) 107-115
20. Conover C.A., Lee P.D., Riggs B.L., and Powell D.R. Insulin-like growth factor-binding protein-1 expression in cultured human bone cells: regulation by insulin and glucocorticoid. Endocrinology 137 (1996) 3295-3301
21. Akune T., Ogata N., Hoshi K., Kubota N., Terauchi Y., Tobe K., et al. Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J Cell Biol 159 (2002) 147-156
22. Maor G., and Karnieli E. The insulin-sensitive glucose transporter (GLUT4) is involved in early bone growth in control and diabetic mice, but is regulated through the insulin-like growth factor I receptor. Endocrinology 140 (1999) 1841-1851
23. Jiang J., Lichtler A.C., Gronowicz G.A., Adams D.J., Clark S.H., Rosen C.J., et al. Transgenic mice with osteoblast-targeted insulin-like growth factor-I show increased bone remodeling. Bone 39 (2006) 494-504
24. Bouxsein M.L., Rosen C.J., Turner C.H., Ackert C.L., Shultz K.L., Donahue L.R., et al. Generation of a new congenic mouse strain to test the relationships among serum insulin-like growth factor I, bone mineral density, and skeletal morphology in vivo. J Bone Miner Res 17 (2002) 570-579
25. Campos Pastor M.M., López-Ibarra P.J., Escobar-Jiménez F., Serrano Pardo M.D., and García-Cervigón A.G. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int 11 (2000) 455-459
26. Irwin R., Lin H.V., Motyl K.J., and McCabe L.R. Normal bone density obtained in the absence of insulin receptor expression in bone. Endocrinology 147 (2006) 5760-5767
27. Miyata T., Notoya K., Yoshida K., Horie K., Maeda K., Kurokawa K., et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 8 (1997) 260-270
28. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
29. Rosen E.D., Sarraf P., Troy A.E., Bradwin G., Moore K., Milstone D.S., et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4 (1999) 611-617
30. Lazarenko O.P., Rzonca S.O., Hogue W.R., Swain F.L., Suva L.J., and Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 86 (2007) 2669-2680
31. Okazaki R., Toriumi M., Fukumoto S., Miyamoto M., Fujita T., Tanaka K., et al. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140 (1999) 5060-5065
32. Soroceanu M.A., Miao D., Bai X.Y., Su H., Goltzman D., and Karaplis A.C. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 83 (2004) 203-216
33. Lecka-Czernik B., Ackert-Bicknell C., Adamo M.L., Marmolejos V., Churchill G.A., Shockley K.R., et al. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148 (2007) 903-911
34. Justesen J., Stenderup K., Ebbesen E.N., Mosekilde L., Steiniche T., and Kassem M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology (2001) 165-171
35. Baynes K.C., Boucher B.J., Feskens E.J., and Kromhout D. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 40 (1997) 344-347
36. Gysemans C., Van Etten E., Overbergh L., Verstuyf A., Waer M., Bouillon R., et al. Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-beta in combination with an analogue of 1alpha,25-dihydroxyvitamin-D3. Clin Exp Immunol 128 (2002) 213-220
37. Khamaisi M., Regev E., Yarom N., Avni B., Leitersdorf E., Raz I., et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 92 (2007) 1172-1175
38. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 130 (2007) 456-469
39. Hamrick M.W. Perspectives: leptin and bone : a consensus emerging?. BoneKey-Osteovision 4 2007 (2007) 99-107
40. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L., et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 11 (2002) 1305-1317
41. Yakar S., Rosen C.J., Beamer W.G., Ackert-Bicknell C.L., Wu Y., Liu J.L., et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 110 (2002) 771-781
42. Horcajada-Molteni M.N., Chanteranne B., Lebecque P., Davicco M.J., Coxam V., Young A., et al. Amylin and bone metabolism in streptozotocin-induced diabetic rats. J Bone Miner Res 16 (2001) 958-965